These findings lend further credence to the viability of targeting SCs to treat TLE. As with other genetic and pharmacologic SC ablation strategies, SSK1 produced a similar reduction in p16+ cells and normalization of spatial memory. SSK1, however, displays a stronger protective effect against seizures. In short, SSK1 is a compelling, translationally viable option for senolysis in TLE.
McFall et al. (Mon,) studied this question.